Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors

References

• F. Ruebsam, C.V. Tran, L.S. Li, S.H. Kim, A.X. Xiang, Y. Zhou, J.K. Blazel, Z. Sun, P.S. Dragovich, J. Zhao, H.M. McGuire, D.E. Murphy, M.T. Tran, N. Stankovic, D.A. Ellis, A. Gobbi, R.E. Showalter, S.E. Webber, A.M. Shah, M. Tsan, R.A. Patel, L.A. Lebrun, H.J. Hou, R. Kamran, M.V. Sergeeva, D.M. Bartkowski, T.G. Nolan, D.A. Norris and L. Kirkovsky, 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase, Bioorg. Med. Chem. Lett. 19, (2009), 451–458.
   PubMed Web of Science ®Google Scholar
• I. Stansfield, S. Avolio, S. Colarusso, N. Gennari, F. Narjes, B. Pacini, S. Ponzi and S. Harper, Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid, Bioorg. Med. Chem. Lett. 14, (2004), 5085–5088.
   PubMed Web of Science ®Google Scholar
• K.X. Chen, C.A. Lesburg, B. Vibulbhan and W. Yang, A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors, J. Med. Chem. 55, (2012), 2089–2101.
   PubMed Web of Science ®Google Scholar
• A.C. Krueger, D.L. Madigan, W.W. Jiang, W.M. Kati, D. Liu, Y. Liu, C.J. Maring, S. Masse, K.F. McDaniel, T. Middleton, H. Mo, A. Molla, D. Montgomery, J.K. Pratt, T.W. Rockway, R. Zhang and D.J. Kempf, Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides, Bioorg. Med. Chem. Lett. 16, (2006), 3367–3370.
   PubMed Web of Science ®Google Scholar
• T. Ishida, T. Suzuki, S. Hirashima, K. Mizutani, A. Yoshida, I. Ando, S. Ikeda, T. Adachi and H. Hashimoto, Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: Identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole, Bioorg. Med. Chem. Lett. 16, (2006), 1859–1863.
   PubMed Web of Science ®Google Scholar
• D. Das, J. Hong, S.H. Chen, G. Wang, L. Beigelman, S.D. Seiwert and B.O. Buckman, Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors, Bioorg. Med. Chem. 19, (2011), 4690–4703.
   PubMed Web of Science ®Google Scholar
• M.H. Powdrill, J.A. Bernatchez and M. Gotte, Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B, Viruses 2, (2010), 2169–2195.
   PubMed Web of Science ®Google Scholar
• M. Wang, K. Wang, A. Yan and C. Yu, Classification of HCV NS5B polymerase inhibitors using support vector machine, Int. J. Mol. Sci. 13, (2012), 4033–4047.
   PubMed Web of Science ®Google Scholar
• C. Hansch and T. Fujita, Status of QSAR at the End of the Twentieth Century, in Classical and Three-Dimensional QSAR in Agrochemistry, Vol. 606, American Chemical Society, 1995, pp. 1–12.
   Google Scholar
• A. Yan, Y. Chong, L. Wang, X. Hu and K. Wang, Prediction of biological activity of Aurora-A kinase inhibitors by multilinear regression analysis and support vector machine, Bioorg. Med. Chem. Lett. 21, (2011), 2238–2243.
   PubMed Web of Science ®Google Scholar
• P.V. Khadikar, V. Sharma, S. Karmarkar and C.T. Supuran, QSAR studies on benzene sulfonamide carbonic anhydrase inhibitors: Need of hydrophobic parameter for topological modeling of binding constants of sulfonamides to human CA-II, Bioorg. Med. Chem. Lett. 15, (2005), 923–930.
   PubMed Web of Science ®Google Scholar
• K.X. Chen, H.Y. Xie and Z.G. Li, 2D-QSAR studies on anthranilic acid derivatives: A novel class of allosteric inhibitors of hepatitis C NS5B polymerase, Chinese J. Struct. Chem. 28, (2009), 1217–1225.
   Web of Science ®Google Scholar
• P.D. Patel, M.R. Patel, N. Kaushik-Basu and T.T. Talele, 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors, J. Chem. Inf. Model. 48, (2008), 42–55.
   PubMed Web of Science ®Google Scholar
• I. Musmuca, A. Caroli, A. Mai, N. Kaushik-Basu, P. Arora and R. Ragno, Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors, J. Chem. Inf. Model. 50, (2010), 662–676.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer, S. Riahi, M.R. Ganjali and P. Norouzi, QSAR study of C allosteric binding site of HCV NS5B polymerase inhibitors by support vector machine, Mol. Divers. 15, (2011), 645–653.
   PubMed Web of Science ®Google Scholar
• ADRIANA.Code 2.2, Molecular Networks GmbH, Erlangen, Germany, 2012; software available at http://www.molecular-networks.com, Vol. ADRIANA.Code, Molecular Networks GmbH, Erlangen, Germany. http://www.molecular-networks.com (accessed Dec 2012).
   Google Scholar
• T. Kohonen, Self-organized formation of topologically correct feature maps, Biol. Cybernet. 43, (1982), 59–69.
   Web of Science ®Google Scholar
• C. Cortes and V. Vapnik, Support-vector networks, Mach. Learn. 20, (1995), 273–297.
   Web of Science ®Google Scholar
• sqR. Tedesco, A.N. Shaw, R. Bambal, D. Chai, N.O. Concha, M.G. Darcy, D. Dhanak, D.M. Fitch, A. Gates, W.G. Gerhardt, D.L. Halegoua, C. Han, G.A. Hofmann, V.K. Johnston, A.C. Kaura, N. Liu, R.M. Keenan, J. Lin-Goerke, R.T. Sarisky, K.J. Wiggall, M.N. Zimmerman, and K.J. Duffy, 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase, J. Med. Chem. 49 (2006), pp. 971–983.
   Google Scholar
• G. Burton, T.W. Ku, T.J. Carr, T. Kiesow, R.T. Sarisky, J. Lin-Goerke, A. Baker, D.L. Earnshaw, G.A. Hofmann, R.M. Keenan and D. Dhanak, Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture, Bioorg. Med. Chem. Lett. 15, (2005), 1553–1556.
   PubMed Web of Science ®Google Scholar
• J. de Vicente, R.T. Hendricks, D.B. Smith, J.B. Fell, J. Fischer, S.R. Spencer, P.J. Stengel, P. Mohr, J.E. Robinson, J.F. Blake, R.K. Hilgenkamp, C. Yee, G. Adjabeng, T.R. Elworthy, J. Tracy, E. Chin, J. Li, B. Wang, J.T. Bamberg, R. Stephenson, C. Oshiro, S.F. Harris, M. Ghate, V. Leveque, I. Najera, S. Le Pogam, S. Rajyaguru, G. Ao-Ieong, L. Alexandrova, S. Larrabee, M. Brandl, A. Briggs, S. Sukhtankar, R. Farrell and B. Xu, Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones, Bioorg. Med. Chem. Lett. 19, (2009), 3642–3646.
   PubMed Web of Science ®Google Scholar
• R. Tedesco, D. Chai, M.G. Darcy, D. Dhanak, D.M. Fitch, A. Gates, V.K. Johnston, R.M. Keenan, J. Lin-Goerke, R.T. Sarisky, A.N. Shaw, K.L. Valko, K.J. Wiggall, M.N. Zimmerman and K.J. Duffy, Synthesis and biological activity of heteroaryl 3-(1,1-dioxo-2H-(1,2,4)-benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone derivatives as hepatitis C virus NS5B polymerase inhibitors, Bioorg. Med. Chem. Lett. 19, (2009), 4354–4358.
   PubMed Web of Science ®Google Scholar
• F. Ruebsam, S.E. Webber, M.T. Tran, C.V. Tran, D.E. Murphy, J. Zhao, P.S. Dragovich, S.H. Kim, L.S. Li, Y. Zhou, Q. Han, C.R. Kissinger, R.E. Showalter, M. Lardy, A.M. Shah, M. Tsan, R. Patel, L.A. Lebrun, R. Kamran, M.V. Sergeeva, D.M. Bartkowski, T.G. Nolan, D.A. Norris and L. Kirkovsky, Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase, Bioorg. Med. Chem. Lett. 18, (2008), 3616–3621.
   PubMed Web of Science ®Google Scholar
• J.P. Powers, D.E. Piper, Y. Li, V. Mayorga, J. Anzola, J.M. Chen, J.C. Jaen, G. Lee, J. Liu, M.G. Peterson, G.R. Tonn, Q. Ye, N.P. Walker and Z. Wang, SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase, J. Med. Chem. 49, (2006), 1034–1046.
   PubMed Web of Science ®Google Scholar
• L.S. Li, Y. Zhou, D.E. Murphy, N. Stankovic, J. Zhao, P.S. Dragovich, T. Bertolini, Z. Sun, B. Ayida, C.V. Tran, F. Ruebsam, S.E. Webber, A.M. Shah, M. Tsan, R.E. Showalter, R. Patel, L.A. Lebrun, D.M. Bartkowski, T.G. Nolan, D.A. Norris, R. Kamran, J. Brooks, M.V. Sergeeva, L. Kirkovsky, Q. Zhao and C.R. Kissinger, Novel HCV NS5B polymerase inhibitors derived from 4-(1’,1’-dioxo-1’,4’-dihydro-1’lambda(6)-benzo[1’,2’,4’]thiadiazin-3’-yl)- 5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7’-substituents and initial pharmacokinetic assessments, Bioorg. Med. Chem. Lett. 18, (2008), 3446–3455.
   PubMed Web of Science ®Google Scholar
• A. Gopalsamy, R. Chopra, K. Lim, G. Ciszewski, M. Shi, K.J. Curran, S.F. Sukits, K. Svenson, J. Bard, J.W. Ellingboe, A. Agarwal, G. Krishnamurthy, A.Y. Howe, M. Orlowski, B. Feld, J. O’Connell and T.S. Mansour, Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site, J. Med. Chem. 49, (2006), 3052–3055.
   PubMed Web of Science ®Google Scholar
• P.S. Dragovich, J.K. Blazel, D.A. Ellis, Q. Han, R. Kamran, C.R. Kissinger, L.A. LeBrun, L.S. Li, D.E. Murphy, M. Noble, R.A. Patel, F. Ruebsam, M.V. Sergeeva, A.M. Shah, R.E. Showalter, C.V. Tran, M. Tsan, S.E. Webber, L. Kirkovsky and Y. Zhou, Novel HCV NS5B polymerase inhibitors derived from 4-(1’,1’-dioxo-1’,4’-dihydro-1’lambda(6)-benzo[1’,2’,4’]thiadiazin-3’-yl)- 5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents, Bioorg. Med. Chem. Lett. 18, (2008), 5635–5639.
   PubMed Web of Science ®Google Scholar
• J. de Vicente, R.T. Hendricks, D.B. Smith, J.B. Fell, J. Fischer, S.R. Spencer, P.J. Stengel, P. Mohr, J.E. Robinson, J.F. Blake, R.K. Hilgenkamp, C. Yee, J. Zhao, T.R. Elworthy, J. Tracy, E. Chin, J. Li, A. Lui, B. Wang, C. Oshiro, S.F. Harris, M. Ghate, V.J. Leveque, I. Najera, S. Le Pogam, S. Rajyaguru, G. Ao-Ieong, L. Alexandrova, B. Fitch, M. Brandl, M. Masjedizadeh, S.Y. Wu, S. de Keczer and T. Voronin, Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: Synthesis and optimization studies of benzothiazine-substituted tetramic acids, Bioorg. Med. Chem. Lett. 19, (2009), 5648–5651.
   PubMed Web of Science ®Google Scholar
• F.E. Grubbs, Sample criteria for testing outlying observations, Ann. Math. Statist. 21, (1950), 27–58.
   Google Scholar
• MOE (The Molecular Operating Environment) 2010. Chemical Computing Group Inc, Japan, 2010; software available at http://www.chemcomp.com/, Vol. MOE (The Molecular Operating Environment), Version .2010; software available from Chemical Computing Group Inc.
   Google Scholar
• Sonnia 4.0. Molecular Networks GmbH, Erlangen, Germany, 2012; software available at http://www.molecular-networks.com/, Vol. SONNIA can be obtained from Molecular Networks GmbH, Erlangen, Germany.
   Google Scholar
• J. Sadowski and J. Gasteiger, From atoms and bonds to three-dimensional atomic coordinates: Automatic model builders, J. Chem. Rev. 93, (1993), 2567–2581.
   Web of Science ®Google Scholar
• D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward and K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, J. Med. Chem. 45, (2002), 2615–2623.
   PubMed Web of Science ®Google Scholar
• J.L. Rodgers and W.A. Nicewander, Thirteen ways to look at the correlation coefficient, Am. Stat. 42, (1988), 59–66.
   Web of Science ®Google Scholar
• C.C. Chang and C.J. Lin, Libsvm; Software available at http://www.csie.ntu.edu.tw/~cjlin/libsvm, Vol. C.C. Chang, C.J. Lin, LIBSVM: A library for support vector machine. Software available at http://www.csie.ntu.edu.tw/~cjlin/libsvm, 2001.
   Google Scholar
• C.A. Boneau, The effects of violations of assumptions underlying the t test, Psychol. Bull. 57, (1960), 49–64.
   PubMed Web of Science ®Google Scholar